Annual Report for the year 2010-2011

1. Introduction about the Department including activities:

The Department of Oncology is responsible for diagnosing and treating all cases of hematological malignancies as well as giving chemotherapy to majority of the solid tumors in various settings. The Department of Medical Oncology is committed to improving the diagnosis and treatment of adult patients with cancer. To meet this mission there is a broad range of basic Research, Clinical Research, Patient Care and Teaching.

The consultants of this Department are Qualified and highly experienced. Their efforts by committing themselves to patient care has resulted in improved survival rates and reduced Morbidity’s.

The Department practices high dose rate chemotherapy, day care therapy. The Nursing Staffs as well as the Junior doctors are well versed in caring for patients with long term Venous Access Devices and Implantable Codes.

The Department of Medical Oncology consists of 6 faculty members and 10 Post Graduate students (D.M. Medical Oncology). The Department runs out patient clinic services were every day about 150 to 200 patients visit the OPD per day. At a time, around 50 in-patients are admitted for chemotherapy, management of complications and for work-up.

For every new patient, after a diagnosis is established, there is Departmental meeting for planning of treatment. The Department has its own medical minor O.T. were all the minor procedures such as Bone Marrow Aspirations / Biopsy, Ascetic and Pleural Tapping, True Cut Biopsy etc, carried out under full aseptic precautions.

The Department also provides Specialty for autologous cell transplantation for malignancies like non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, and multiple myeloma.

ACADEMIC ACTIVITIES:
The academic activities of the department includes;
- Long seminars on every Tuesdays
- Short seminars on every Wednesdays
- Journal club on every Thursdays
- Multi disciplinary seminar on every Fridays
- Case presentations on every Saturdays

COURSES OFFERED:
The Department provides prestigious D.M. degree in Medical Oncology. Every year 2 candidates are selected by All India Entrance Examination conducted by the Rajiv Gandhi University of Medical Sciences. Out of this, 1 seat is reserved for in-service candidates However, the No of DM seats is enhanced to 6 from August 2010.

The course is of 3 years duration. The examinations are held in the month of June- July. The examinations are conducted in 2 parts, the first part comprises of a written examination for 90 marks. The paper contains 90 multiple choice questions. Around 5 candidates are selected on the basis of merit list of this theory examination. The second part comprises interview of 10 marks. The final merit list is made by adding both theory and interview marks. Candidates are selected on the basis of final merit list.

During the course, the students are exposed to all kinds of treatment for all solid tumors and hematological malignancies. Apart from this, they have special posting during which they are posted in pediatric oncology, hematology, and various other oncology Departments.

M.D. Medicine students from various medical colleges in Karnataka are getting trained in oncology during their special posting to KMIO.

2. Conferences / Seminars / work-shops conducted by the Department for 2010-2011:


3. Major equipments added during the year 2010-2011:

Nil

4. Staff positions: (01.04.2010-31.03.2011)

Dr K.C. Lakshmaiah MBBS, M.D. D.M
Professor and Head of Department.

Dr T.M. Suresh MBBS, M.D. D.M
Professor

Dr Rani S Acharya MBBS, M.D
Associate professor

Dr D. Lokanatha MBBS, M.D. D.M
Associate professor

Dr K. Govind Babu MBBS, M.D. D.M
Associate professor

Dr Linu Abraham Jacob MBBS, M.D. D.M
Assistant professor
Post graduates:
- Dr Tejinder Singh
- Dr C.T.Satheesh
- Dr L.K.Rajeev
- Dr Mukul Goyal
- Dr Vineetha Unnikrishnan
- Dr Rohan Bhise
- Dr A.H.Rudresha
- Dr K.N.Lokesh
- Dr Samit Purohit
- Dr B.K.Vivek
- Dr Anil Kumar

Shri Para Shiva Murthy
ECG technician

Shri B.S. Govind Raju
ECG technician

Smt B Sukanya
Clerk cum typist – till 18th May 2009

Smt C Vanamala
Clerk cum typist - since 18th May 2009 to till date

5. Research activities / projects, completed projects, ongoing projects and new projects undertaken during this period: (1.4.2009 To 31.3.2010)

Dr K.C.Lakshamaiah:
Completed Projects (Global Trials)


Clinical Evaluation of Alpha Interferon in Chronic Myeloid Leukemia in Chronic Phase. March 1993-1995

NATIONAL TRIALS:

Clinical Evaluation of Alpha Interferon in Chronic Myeloid Leukemia in Chronic Phase. March 1993-1995
Phase IV Clinical study of Itracamazole in immunocompromised patients receiving Concurrent Chemotherapy and Radiotherapy in Squamous Cell Head and neck Cancer. April 1995-1996.

COMPLETED PROJECTS:

Randomized Clinical Trial of Cisplatin and Paclitaxel based chemotherapy in different sequencing along with Radiotherapy and Surgery in Stage III & IV resectable Squamous Cell Carcinoma of Oral Cavity (Dec. 2000-2002)

A Phase II Multicentre uncontrolled trial BAY 563722 in patients with advanced hepato cellular carcinoma (August 2002)

A randomized trial of Pivanex plus Docetaxel or Docetaxel Mono therapy in patients with chemotherapy resistant advanced Non Small Cell Carcinoma of Lung (NSCLC) (July 2003-2005).

A Randomized phase 3 study of Efficacy and safety of glufoosfamide compared with best supportive care in metastatic, Pancreatic adenocarcinoma previously treated with gemcitabine (July 2006)

A Multinational, randomized, double-blind, placebo-controlled study to evaluate and safety to evaluate and safety of AVE5026 in the prevention of Venous Thromboembolism (VTE) in Cancer patient at high risk for VTE and who are undergoing chemotherapy (30 Oct. 2008)


A Phase 1b/2 trial of AMG 479 or AMG 102 in Combination with Platinum based chemotherapy as First Line treatment for Extensive Stage Small Cell Lung Cancer (Apr 2009)

- ONGOING PROJECTS:

A RANDOMIZED CONTROLLED OPEN LABEL PHASE II/III study to evaluate the Efficacy and safety of Herceptin + oral Arimidex (AnastroZole) compared with Arimidex alone as first and second line treatment in Postmenopausal women ER and PR +ve patients HER 2 over expressing Metastatic Breast Cancer. (Dec. 2005)

A Randomized open Label, Multicentre, phase 3 study of Epotein alfa Plus standard supportive care in anemic patients with metastatic breast cancer receiving first line standard chemotherapy (July 2006)
A Phase 2, Multicentre, open label, randomized Trial of AMG 706 or Bevacizumab in Combination with Paclitaxel and Carboplatin for advanced Non Squamous Non Small Cell Lung Cancer (Dec 2007)

A Randomized Doubled blind, multicenter study of Denosumab compared with zoledronic acid (zometa) in the treatment of bone metastasis in subject with advanced breast cancer. June 2007

A Phase 3, Multicentre, randomized placebo controlled double blind trial of AMG 706 in combination with Paclitaxel and Carboplatin for Advanced Non Small Cell Lung Cancer (Oct 2007)

Dr T.M. Suresh:
Nil

Dr. Rani S. Acharya:
Nil

Dr. D. Lokanatha:

PROJECTS COMPLETED

- PPHM 0701: A Phase II Safety Efficacy study of Bavituximab Plus Paclitaxel and Carboplatin in patients with previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

- An open label, dose finding, prospective, multi-center, Randomized, Parallel group study to assess the efficacy and safety of three different dose levels of AV1-014 (G-CSF) compared with a standard dose of Neupogen® in Breast Cancer patients at high (>20%) risk for chemotherapy induced severe neutropenia.

- A Randomized, Double blind, Multicentre Phase II/III study to compare the Efficacy of Cediranib (RECENTIN TM, AZD2171) in Combination with 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination with FOLFOX in patients with previously untreated Metastatic in
Combination with FOLFOX in Patients with previously Untreated Metastatic Colorectal Cancer.

- A Phase II Study to Determine the Safety, Efficacy, and Pharmacokinetics of multiple Intravenous Doses of ALD518 80 mg, 160 mg, and 320 mg Versus Placebo Administered to patients with Non-Small Cell Lung Cancer-Related Fatigue and Cachexia.

- A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC followed by Ixabepilone compared to sequential AC followed by Paclitaxel in women with early stage Breast Cancer not overexpressing HER-2 and Estrogen Receptors.

- NU 07B1:- A Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination with Paclitaxel in Patients with Locally Recurrent or Metastatic Breast Cancer.

**ONGOING PROJECTS DETAIL:**

- (EGF:106903 NEO ALTTO) A Randomized Phase III Neo-Adjuvant Study of either Trastuzumab alone, concurrent Trastuzumab plus Lapatinib, sequential therapy of Trastuzumab followed by Lapatinib, or Lapatinib alone for patients with breast cancer done in collaboration with the Breast International Group.

- Protocol Code: Zen-01/2006, A Multicentric open label Phase III study to evaluate the safety and efficacy of Rituximab (Zenotech) in Non Hodgkin’s Lymphoma (Version 03 dated 12\textsuperscript{th} Nov 2009 supersedes version 02 dated 12\textsuperscript{th} May 2008)

**Dr.K.Govind Babu:**

**PROJECTS COMPLETED**

- A Multi-Center, Open Label, Parallel group, Randomized, Phase IIB clinical trial to evaluate the safety and efficacy of Co-Factor and 5-FU versus Leucovorin and 5FU in subjects with metastatic Colorectal Carcinoma.

- A Phase III, Randomized, double-blind, multi-centre, parallel-group study to assess the efficacy of ZD6474 (ZACTIMA \textsuperscript{TM}) versus Erlotinib (TARCEVA \textsuperscript{®} in patients with locally advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) after failure of at least one prior Cytotoxic chemotherapy.
- A Multicentric study to evaluate Palonosetron and Ondansetron in chemotherapy induced nausea and vomiting. Sponsor: Dr. Reddy’s Laboratories

- A IPL-IBT-P05-5 entitled “A prospective, non-comparative, open label, Multicenter study to evaluate safety and efficacy of pegfilgrastim (IPL-P05) for prevention of Neutropenia in the patients receiving cancer chemotherapy

- Open-label, multicentre, controlled study of exemestane (Aromasin®) with or without celecoxib (Celebrex®) in postmenopausal women with advanced breast cancer (ABC) having progressed on tamoxifen”. A phase III study of DPPE (Tesmilifene) combined with Epirubicin and Cyclophosphamide versus Epirubicin and Cyclophosphamide alone as First-line Treatment in Metastatic-Recurrent Breast Cancer.

- An open label, single-arm study to evaluate the efficacy and safety of Rituximab in CD20 positive Diffuse Large B cell Lymphoma when given along with CHOP chemotherapy

- International, Randomized, Open-Lable, Phase 3 trial of paclitaxel/carboplatin plus Pf-3512676 Versus Paclitaxel/Carboplatin alone as first line treatment of patients with Advanced Non-Small Cell Lung Cancer.

- A randomized, multicenter therapeutic confirmatory study to evaluate the efficacy and safety of Proxinium™ plus best supportive care versus best supportive care alone in patients with recurrent squamous cell carcinoma of the Head and Neck who have received at least one prior chemotherapy regimen for recurrent disease


- A Multinational Randomized, Double Blind study comparing Aflibercept versus placebo in patients treated with second-Line Docetaxel after failure of one platinum based therapy,for locally advanced or Metastatic Non-small cell Lung Cancer (NSCLC)

- Open Lable , Randomized, Comparative Multicenter Study to Assess Safety and Efficacy of BIOMAb- EGFR (Nimotuzumab) in Combination with Chemotherapy versus Chemotherapy alone in the treatment of Patient with stage III/IV Non Small Cell Lung Cancer(NSCLC).

• Protocol CLR_09_01, study titled phase 1 safety, tolerability, and pharmacokinetic study of Docetaxel nano-dispersion: A randomized, open label, dose ranging, active controlled, comparative parallel groups, and multi-centric study.

ONGOING PROJECTS DETAILS:

• (OMB110911) A Phase III, Open Label, Randomized, Multicenter Trial of Ofatumumab added to Chlorambucil vs. Chlorambucil Monotherapy in Previously Untreated Patients with Chronic Lymphocytic Leukemia.

• (OMB110913) A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in subjects with relapsed Chronic Lymphocytic Leukemia.

• Protocol CLR_10_13, study titled Efficacy and safety of Paclitaxel nano-dispersion concentrate for injection (PICN) in subjects with metastatic breast cancer: A randomized, open label, active controlled, comparative, parallel group, and multi-centric study.

• Ref: F: Hoffmann-La Roche Ltd. – B021129
  MARK – A Phase II Biomarker Identification Trial for Erlotinib (Tarceva®) in patients with Advanced Pancreatic Carcinoma.

• A Multicentre Phase I Study of Cremophor Free Paclitaxel Nonoparticle In Advanced Breast Cancer.

Dr. Linu Abraham Jacob:

Completed Project:

A Phase II randomized study of Carboplatin/Paclitaxel with or without CS-7017 in Chemothreapy naïve subjects with Metastatic Non-Small Cell Lung Cancer.

Ongoing Project

An open Lable Randomised,parallel Group, Multicenter study to compare Zoladex 10.8mg given every 12 weeks with Zoladex 3.6mg given every 4 weeks in pre-menopausal Women with Oestrogen Receptor positive advanced Breast Cancer.

6. Participation at Conference/Seminar/Workshops During the Year 2010-2011 (1.4.2010 – 31.3.2011)

Dr. K.C. Lakshmaiah:
- Participated as a Speaker for COPE –CME-2010 (Cancer Institute Orientation Program for DM Medical Oncology Exam) National CME for final year DM students on 04.04.2010 at Cancer Institute (WIA), Chennai.

- Participated in selection of DNB candidates by the HCG groups of Hospitals Bangalore, on 30.04.2010.

- Participated in national CME on Chronic Myeloid Leukemia 2010 held on 22.05.2010 at Cancer Institute (WIA), Adyar, Chennai-20, and delivered a talk on “Kidwai Institute Experience with Imatinib”.

- Annual Meeting of European society of Medical Oncology – ESMO-2010 at Milan, Italy from 8th October to 12th October 2010

- Delivered Lecture on “Physical Consequences of the treatment” in the pre conference workshop of AGOICON2010 on 12th November 2010

- Participated as a faculty in “Unresolved issues in Oncology” CME at New Delhi on 5.12.2010 and delivered Lecture on “Management of Lung Cancers-2010 and beyond”


**LOCAL INSPECTION.**

- To be a member of Local Inspection Committee of DM Medical Oncology Course in M.S. Ramaiah Medical College Bangalore, on 16.04.2010 and in Vaidehi Institute of Medical Sciences Bangalore on 17.04.2010.

- Participated in the first meeting of Post Graduate Super Specialty Entrance test Committee 2010 convened on 03.05.2010 at Rajiv Gandhi University of Health Sciences.

**MCI Inspection**

- Assessment of physical and other teaching facilities available at Sri Venkateshwara Institute Of Medical Sciences Tirupati, Starting of M.Ch. (Surgical Oncology) Course under SVIMS University Tirupati on 09.07.2010

- MCI Inspection work to start DM medical Oncology Course at Amrita School of Medicine, Kochi, Kerala on 30.08.2010.

- Assessment of physical and other teaching facilities available at the Regional Cancer Center, Trivandrum, starting of DM( Medical Oncology) Course on 11.01.2011
• Assessment of physical and other teaching facilities available at Sri Venkateshwara Institute Of Medical Sciences Tirupati, Starting of M.Ch. (Surgical Oncology) Course under SVIMS University Tirupati on 09.07.2010

Examiner
• Participated in the first meeting of Post Graduate Super Specialty Entrance test Committee 2010 convened on 03.05.2010 at Rajiv Gandhi University of Health Sciences
• Examiner for DM Medical Oncology Post Graduate Students of Tamil Nadu Dr. M.G.R. Medical University, Guindy Chennai to Conduct practical / Clinical Viva-Voce Examination at Madras Medical College, Chennai at 09.08.2010

Dr. T.M. Suresh:

• Participated in the American Society Clinical Oncology’s 46th Meeting held at McCormic Place in Illinois, Chicago, USA between 4-8th June 2010 as a Consultant.

Dr Rani S Acharya
• CME on Lung Cancer – update on Non Small Cell Lung Cancer on 16.07.2010, KMIO

Dr. D. Lokanatha
• Conference of American Society of Hematology held at Orlando, USA between 3-7 December 2010.

Dr. K. Govind Babu:
• Residential Training Course in Oxford UK as part of INDOX Training Scheme at U.K. from 26-30 July 2010 – “How to do Research on Therapeutic Inventions: Protocol Preparation”.
• “Expert Dialogues : Optimizing Renal Cell Ca Treatment “ at Paris, France between 28-29 Jan 2011
• Breast Cancer Working Group at Tata Memorial Hospital, Mumbai, at R.D.Choksi Auditorium on 5.2.2011
• Indian Cancer Congress – 2011, the Biennial Joint Conference of ISMPO (Indian Society of Medical & Pediatric Oncology) and ISO (Indian Society of Oncology) at Bhubaneswar on 11,2,2011 to be a panelist for discussion on “Complications & Its Management in Head & Neck Cancer”.
• Faculty at ICON – Indian Co-operative Oncology Network between 11-13 March 2011 at Hotel Hyatt Regency, New Delhi.

**EXAMINER / SELECTION EXPERTS/ EVALUATOR**

• External Expert for Selection Committee Proceedings by Nizam Institute of Medical Sciences, Hyderabad on 19.6.2010 to Select Associate Professor in Medical Oncology.

• Examiner for Clinical/Viva-Voce D.M. (Medical Oncology) at Nizam Institute of Medical Sciences, Hyderabad on 20.7.2010.

• Examiner for D.M. (Medical Oncology) Post Graduates of Dr.MGR Medical University, Chennai, on 7.2.2011 at Madras Medical College & General Hospital, Chennai.

• Assessor for the Evaluation of Answer Sheets Papers of Medical Oncology Paper II of the DNB Final Theory Examination which was held on 11 & 12 December 2010 by the National Board of Examinations on 24th & 25th March 2011.

**Dr.Linu Abraham Jacob:**

• Asian Oncology Summit held at Hong Kong between 8-10 April 2010 and presented a poster on “Invasive Fungal Infections in Hematological Malignancies at a Regional Cancer Institute – Role of Penfungal PCR”.

• 10th FHNO-IFHNOS 2010 Conference between 13-15th October 2010 at Taj Residency, Bengaluru.

  Best of ASCO Annual Meeting 2010 : July 10-11th 2010 at Hyderabad India

  Promote India Meeting 19th December 2010, Bhopal as Speaker.

7. **Papers Published in National and International Journals along with the title of the Paper, Authors Name, Name of Journal (1.4.2010 to 31.3.2011):**

**Dr.K.C.Lakshmaiah:**

• Association of Primary Central Nervous System Lymphomas with the Epstein-barr virus. Neurology India April-June 2003 Vol 51 (237-239) Issue 2

• Simultaneous Occurrence of Multiple Myeloma and Acute Myeloid Leukemia. Turk J Hematol 2006 :23:209-211
• Primary Bone Lymphoma: A report of two cases and review of the literature
  Published in Journal of Cancer Research and Therapeutics
  Date of web publication 29.Nov.2010

Dr. T. M. Suresh:

Nil

Dr. D. Lokanatha:

• Cutaneous Metastasis in a Case of Carcinoma Stomach. Austral-Asian Journal of
  Cancer ISSN-0972-2556, Vol.7, No.4, October 2008

• Treatment outcome and cost-effectiveness analysis of two chemotherapeutic
  regimens (BEP vs. VIP) for poor-prognosis metastatic germ cell tumors.

• A rare sequential occurrence of chronic lymphocytic leukemia following chronic
  myeloid leukemia.

Examinership

• Gujarat University – Ahmedabad
• Custodian – Rajiv Gandhi University of Health Sciences - Bangalore
• Custodian – Diplomat of National Board – New Delhi
• Paper Setting for - Gujarat University , Ahmedabad.

Dr. K. Govind Babu:

Pain Management in Non-Small Cell Lung Cancer
Journal of Thoracic Oncology, June 2011
INVITED TALKS:

- “How to do Research on Therapeutic Inventions: Protocol Preparation” in Oxford UK as part of INDOX Training Scheme at U.K. from 26-30 July 2010

Dr. Linu Abraham Jacob:

Primary Bone Lymphomas : A report of Two Cases and Review of Literature

D.Lokanatha, Linu A Jacob, Rajashekar Halkud


OUT-PATIENTS

<table>
<thead>
<tr>
<th></th>
<th>Male</th>
<th>Female</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Cases</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unit I</td>
<td>529</td>
<td>355</td>
<td>884</td>
</tr>
<tr>
<td>Unit II</td>
<td>342</td>
<td>204</td>
<td>546</td>
</tr>
</tbody>
</table>

Follow-up Cases

<p>| | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Unit I</td>
<td>6242</td>
<td>4076</td>
<td>10318</td>
</tr>
</tbody>
</table>

<p>| | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Unit II</td>
<td>3496</td>
<td>2164</td>
<td>5660</td>
</tr>
</tbody>
</table>

IN-PATIENTS:

Admissions:

<p>| | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Unit I</td>
<td>150</td>
<td>92</td>
<td>242</td>
</tr>
</tbody>
</table>

<p>| | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Unit II</td>
<td>81</td>
<td>82</td>
<td>163</td>
</tr>
</tbody>
</table>
## Re-admissions:

<table>
<thead>
<tr>
<th></th>
<th>Unit I</th>
<th></th>
<th>Unit II</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1565</td>
<td>1572</td>
<td>3137</td>
<td></td>
</tr>
<tr>
<td></td>
<td>346</td>
<td>831</td>
<td>1177</td>
<td></td>
</tr>
</tbody>
</table>

## Discharges:

<table>
<thead>
<tr>
<th></th>
<th>Unit I</th>
<th></th>
<th>Unit II</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1450</td>
<td>1431</td>
<td>2881</td>
<td></td>
</tr>
<tr>
<td></td>
<td>739</td>
<td>720</td>
<td>1459</td>
<td></td>
</tr>
</tbody>
</table>

## Deaths:

<table>
<thead>
<tr>
<th></th>
<th>Unit I</th>
<th></th>
<th>Unit II</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>66</td>
<td>47</td>
<td>113</td>
<td></td>
</tr>
<tr>
<td></td>
<td>41</td>
<td>33</td>
<td>74</td>
<td></td>
</tr>
</tbody>
</table>
1. **Introduction about the Department including activities:**

The Department of Oncology is responsible for diagnosing and treating all cases of hematological malignancies as well as giving chemotherapy to majority of the solid tumors in various settings. The Department of Medical Oncology is committed to improving the diagnosis and treatment of adult patients with cancer. To meet this mission there is a broad range of basic Research, Clinical Research, Patient Care and Teaching.

The consultants of this Department are Qualified and highly experienced. Their efforts by committing themselves to patient care has resulted in improved survival rates and reduced Morbidity’s.

The Department practices high dose rate chemotherapy, day care therapy. The Nursing Staffs as well as the Junior doctors are well versed in caring for patients with long term Venous Access Devices and Implantable Codes.

The Department of Medical Oncology consists of 6 faculty members and Post Graduate students (D.M. Medical Oncology). The Department runs out patient clinic services were every day about 150 to 200 patients visit the OPD per day. At a time, around 50 in-patients are admitted for chemotherapy, management of complications and for work-up.

For every new patient, after a diagnosis is established, there is Departmental meeting for planning of treatment. The Department has its own medical minor O.T. were all the minor procedures such as Bone Marrow Aspirations / Biopsy, Ascetic and Pleural Tapping, True Cut Biopsy etc, carried out under full aseptic precautions.

The Department also provides Specialty for autologous cell transplantation for malignancies like non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, and multiple myeloma.

**ACADEMIC ACTIVITIES:**

The academic activity of the department includes:
1. Long seminars and every Tuesdays
2. Short seminars and every Wednesdays
3. Case presentations on every Saturdays
4. Multi disciplinary seminar on every Fridays

**COURSES OFFERED:**

The Department provides prestigious D.M. degree in Medical Oncology. Every year 2 candidates are selected by All India Entrance Examination conducted by the Rajiv Gandhi University of Medical Sciences. Out of this, 1 seat is reserved for in-service candidates.

The course is of 3 years duration. The examinations are held in the month of June- July. The examinations are conducted in 2 parts, the first part comprises of a written examination for 90 marks. The paper contains 90 multiple choice questions. Around 5 candidates are selected on the basis of merit list of this theory examination. The second part comprises interview of 10 marks. The final merit list is made by adding both theory and interview marks. Candidates are selected on the basis of final merit list.

During the course, the students are exposed to all kinds of treatment for all solid tumors and hematological malignancies. Apart from this, they have special posting during which they are posted in pediatric oncology, hematology, and various other oncology Departments.

M.D. Medicine students from various medical colleges in Karnataka are getting trained in oncology during their special posting to KMIO.

2. **Conferences / Seminars / work-shops conducted by the Department for 2009-2010:**

- One Day CME on “Plasma Cell Dyscrasis” on 21st November 2009 at the KMIO Auditorium.

- One day Programme on “Update in NeuroEndocrine Tumor” at KMIO Auditorium on 27th March 2010.

3. **Major equipments added during the year 2009-2010:**

BPL Six Channel ECG Machine Cardiart 8108 R

4. **Staff positions:**

Dr K.C. Lakshmaiah MBBS, M.D. D.M
Professor and Head of department.

Dr T.M.Suresh MBBS, M.D. D.M
Professor

Dr Rani S Acharya MBBS, M.D
Associate professor
Dr D. Lokanatha MBBS, M.D. D.M
Associate professor

Dr K. Govind Babu MBBS, M.D. D.M
Associate professor

Dr Linu Abraham Jacob MBBS, M.D. D.M
Assistant professor

Post graduates:
❖ Dr Ankit Jain
❖ Dr Sajeevan
❖ Dr Rajeev L.K.
❖ Dr Tejinder Singh
❖ Dr. C.T.Sateesh
❖ Dr L.K.Rajeev
❖ Dr.Mukul Goyal

Shri Para Shiva Murthy
ECG technician

Shri B.S. Govind Raju
ECG technician

Smt C.Vanamala
Clerk cum typist

5. Research activities / pro projects, completed projects, ongoing projects and new projects undertaken during this period: (1.4.2009 To 31.3.2010)

Dr K.C.Lakshamaiah:

- Boehringer Ingelheim Protocol Number 1199.13: Multicentre, randomized, double-blind, Phase III trial to investigate the efficacy and safety of oral 1120 plus standard docetaxel therapy compared to placebo plus standard docetaxel therapy in patients with stage III b/IV or recurrent non small cell lung cancer after failure of first line chemotherapy. PAREXEL Number 90237 (19 May 2009) Ongoing.

Dr T.M.Suresh:

Nil

Dr.Rani S.Acharya:
Dr.D.Lokanatha:

**Ongoing Projects**

- INCB7839-201: A Phase ½, Modified Dose Escalation, Open Label Trial to Determine the Therapeutic Effect and safety of INCB007839 Combined with Trastuzumab in patients with previously untreated HER2 positive Metastatic Breast Cancer.

- L00070 IN 303 B0 “Phase III study of vinflunine plus gemcitabine versus Paclitaxel plus gemcitabine in patients with unresectable, locally recurrent or metastatic breast cancer after prior anthracycline based adjuvant chemotherapy

Dr.K.Govind Babu:

**Ongoing Projects**

- (OMB110911) A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in subjects with relapsed Chronic Lymphocytic Leukemia

- (OMB110913) A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in subjects with relapsed Chronic Lymphocytic Leukemia

- A Multicentre Phase I Study of Cremophor Free Paclitaxel Nonoparticle In Advanced Breast Cancer.

Dr.Linu Abraham Jacob:

Nil

6. **Participation at Conference/Seminar/Workshops During the Year 2009-2010 (1.4.2009 – 31.3.2010)**

Dr.K.C.Lakshmaiah:

- CHAIR DECISION on Management of Colorectal Cancer on 18th and 19th April 2009 at LAP ONCO-2009 at NIMHANS Convention Centre.

- Participated as Speaker on the role of Erythropoietin Solid Tumors and use of Growth Factors in the Management of Chemotherapy induced Toxicity. Video Based
Conference in Gynaec oncology (VCG)) – 2009 held at KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY, BANGALORE on 11th and 12th April 2009.

- Presented a paper as poster in ECCC and ESSMO Meeting held in Berlin Germany on 20-24 September 2009. A Phase 2 Multicentre open label randomized trial of AMG 706 or Bevacizumab in combination with Paclitaxel and Carboplatin for advanced non squamous non small cell lung cancer.

Dr. T. M. Suresh:
- Attended Second Area Oncology Medical Conference in Erb-B2 Driven Breast Cancer. Izmir Turkey on 29th September 2009

Dr. Rani S Acharya
- One day CME on Plasma Cell Dyscrasia on 21-11-2009 at KMIO.

Dr. D. Lokanatha:
- INDOX Cancer Research network meeting in Hyderabad 26th to 27th June 2009
- CME on Myeloma and Lymphoma on 1st August 2009

Dr. K. Govind Babu:
- Video Based Conference in Gynaec Oncology (VCGO) -2009 on 11th & 12th, April 2009. Organized by Dept of Gynaec Oncology Kidwai Memorial Institute of Oncology Bangalore.
- 21st Icon meeting between 18-20 Sep 2009, at Tata Memorial Hospital, Mumbai.
- 31st CME in Internal Medicine between 3-8 Oct 2010, at Rajiv Gandhi University Of Health Sciences, Bangalore.
- Annual Conference of Indian Society of Medical & Pediatric Oncology 3rd -25th October -2009 at srinagar India.
- 7thWCI-TMH Annual Breast Cancer Conference at the RD Choksi Auditorium, Tata Memorial Hospital, Mumbai, from 30 Oct -1 Nov-2009.
- 32nd San Antonio Breast Cancer Symposium between 9-13 Dec 2009 at San Antonio, Texas, USA.
- APICON – 2010 at Jaipur between 7th to 10th January
- Medicine Update Programme between 22nd to 24th Jan 2010. at Mysore.
- Meeting of Indian Pediatric Oncology initiative at New Delhi on 4th and 5th February 2010 at New Delhi
- 22nd Icon Meet – Kolkata 20th to 21st Feb 2010.
- Annual Joint Oncology Conference by Artemis Health Institute, Gurgaon and Memorial Sloan Kettering Cancer Centre New York on 06 & 07 March 2010.

Examinership:

For D.M. Medical Oncology at Tamil Nadu Dr M.G.R. Medical college Chennai on 10th and 11th August 2009
- For DNB students between 12 -13 Dec 2009 at National Board of Examinations New Delhi

Dr. Linu Abraham Jacob:

- Exelixis XL 184-301 Investigators Meeting held at Turkey on Thursday 19th & 20th Friday November 2009 as Co-investigator.
- Pediatric Oncology CME 2010 held at Malabar Institute of Medical Sciences on
- 7th February 2010 as faculty.

5. Papers Published in National and International Journals along with the title of the Paper, Authors Name, Name of Journal (1.4.2008 to 31.3.2009):

Dr. K.C. Lakshmaiah:

- Primary B Cell Non-Hodgkin’s Lymphoma of Tongue. Letter to the Editor Indian Journal Cancer Jan March 2010;47(1):84-6


- To analyze efficacy and safety of pegfilgrastim versus filgrastim in patients with breast cancer. J. Clin Oncol 27, 2009 (Suppl; abstr e20587)

- Retrospective analysis of clinico-pathological profile of triple negative breast cancer – Experience from a tertiary care center from South India. The Breast 2009. Vol 18 (Suppl 1), S 71.0210

**Dr. T. M. Suresh:**

Nil

**Dr. D. Lokanatha:**

- Acute lymphoblastic leukemia with extramedullary relapse in bone
- Chronic myeloid leukemia with osteolytic bone involvement
- Treatment outcome and cost effectiveness analysis of two chemotherapeutic regimens (BEP vs. VIP) for poor prognosis metastatic germ cell tumors
Dr. K. Govind Babu:

Invited Talks

Novel Insights Nutrition for Cancer Patients:

21st Icon meeting between 18-20 Sep 2009, at Tata Memorial Hospital, Mumbai. Novel Insights nutrition for Cancer Patients

Bronchogenic Carcinoma

31st CME in Internal Medicine between 3-8 Oct 2009, at Rajiv Gandhi University Of Health Sciences, Bangalore

- **Nutrition in Cancer Patients**
  Annual Conference of Indian Society of Medical & Pediatric Oncology 23rd -25th October, 2009 at Srinagar, India.

- **Targeted Therapy in Breast Cancer**
  7th WCI-TMH Annual Breast Cancer Conference at the RD Choksi Auditorium, Tata Memorial Hospital, Mumbai, from 30 Oct to 1 Nov, 2009.

- **Targeted Therapy in Oncology**
  Medicine Update Programme between 22nd to 24th Jan 2010, at Mysore

- **Management of advanced Lung Cancer**
  Annual Joint Oncology Conference by Artemis Health Institute, Gurgaon and Memorial Sloan Kettering Cancer Centre New York on 06 & 07 March 2010

Dr. Linu Abraham Jacob:


OUT-PATIENTS

1. New Cases

<table>
<thead>
<tr>
<th></th>
<th>Male</th>
<th>Female</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unit I</td>
<td>523</td>
<td>335</td>
<td>858</td>
</tr>
<tr>
<td>Unit II</td>
<td>344</td>
<td>234</td>
<td>578</td>
</tr>
</tbody>
</table>

1. Follow-up Cases

<table>
<thead>
<tr>
<th></th>
<th>Male</th>
<th>Female</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unit I</td>
<td>8436</td>
<td>7305</td>
<td>15741</td>
</tr>
<tr>
<td>Unit II</td>
<td>4838</td>
<td>4075</td>
<td>8913</td>
</tr>
</tbody>
</table>

IN-PATIENTS:

Admissions:

<table>
<thead>
<tr>
<th></th>
<th>Male</th>
<th>Female</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unit I</td>
<td>302</td>
<td>266</td>
<td>568</td>
</tr>
<tr>
<td>Unit II</td>
<td>174</td>
<td>158</td>
<td>332</td>
</tr>
</tbody>
</table>

Re-admissions:

<table>
<thead>
<tr>
<th></th>
<th>Male</th>
<th>Female</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unit I</td>
<td>1610</td>
<td>1840</td>
<td>3450</td>
</tr>
<tr>
<td>Unit II</td>
<td>858</td>
<td>1009</td>
<td>1867</td>
</tr>
</tbody>
</table>

Discharges:

<table>
<thead>
<tr>
<th></th>
<th>Male</th>
<th>Female</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unit I</td>
<td>1650</td>
<td>1840</td>
<td>3490</td>
</tr>
<tr>
<td>Unit II</td>
<td>878</td>
<td>977</td>
<td>1855</td>
</tr>
</tbody>
</table>

Deaths:

<table>
<thead>
<tr>
<th></th>
<th>Male</th>
<th>Female</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unit I</td>
<td>60</td>
<td>36</td>
<td>96</td>
</tr>
<tr>
<td>Unit II</td>
<td>24</td>
<td>29</td>
<td>53</td>
</tr>
</tbody>
</table>
1. INTRODUCTION ABOUT THE DEPARTMENT INCLUDING ACTIVITIES:

Pediatric Oncology is functioning as a separate unit in the Department of Medical Oncology from July 1992. At the 41st Meeting of Governing Council held on 29th December 2008 it was created as Department of Pediatric oncology.

ACTIVITIES:

The Department trains D.M. students in Medical Oncology and Post-graduate students posted from various medical colleges of Karnataka.

2. CONFERENCES/SEMINAR/WORKSHOPS CONDUCTED BY THE DEPARTMENT:
Nil

3. MAJOR EQUIPMENTS ADDED DURING THE YEAR 2008

Nil

4. STAFF POSITION:

Dr. L. Appaji MBBS, MD, DM : Prof; & HOD
Dr. B. S. Aruna Kumari MBBS, MD, DM : Associate Professor
Dr. M. Padma MBBS, MD, DM : - “ - 
Dr. H. S. Mamatha MBBS : Assistant Surgeon

5. RESEARCH ACTIVITIES/PROJECTS COMPLETED PROJECTS  ONGOING AND NEW PROJECTS UNDERTAKEN DURING THIS PERIOD

Nil

6. PARTICIPATION AT CONFERENCE / SEMINAR/WORKSHOPs DURING THE YEAR 2008-2009 (01.04.2008 to 31.03.2009)

Dr. L. Appaji

- Association of Radiation Oncologists of Indian Scientific Meeting, Karnataka Chapter, April 2008.

- 26th Annual CME Programme by Lake Side Education Trust, July 2008. IAP – BPS CHAFB Pediatric Oncology Update, Command Hospital, Bangalore Sep 2008

- CME Programme in Pediatric at Adichunchanagiri Institute of Medical Sciences Tumkur Oct 2008

Dr. B. S. Aruna Kumari

- Association of Radiation Oncologists of Indian Scientific Meeting, Karnataka Chapter, April 2008.

- IAP – BPS CHAFB Pediatric Oncology update, command hospital, Bangalore Sep 2008
7. PAPERS PUBLISHED IN NATIONAL AND INTERNATIONAL JOURNALS, ALONG WITH THE TITLE OF THE PAPER, AUTHORS NAME, NAME OF JOURNAL (1.04.2008 to 31.03.2009)

Dr. L. Appaji
- Immunohistochemistry on Bone Marrow Paraffin Section for Characterization of Acute Leukemia in an Under Resourced Laboratory
  Journal Clinical Oncology : 26 : 2008
- Acute Toxoplosomosis in Non Stem Cell Transplant patients with Hematological Malignancies : A Study from a Regional Caner Institute in South India
- Coagulation Assessment of children with Acute Lymphoblastic Leukemia –Preliminary Findings
  Indian Journal of Medical – Pediatric oncology
  January to March 2009 Volume 30 issue 1
- Gum Hypertrophy – Unusual presenting feature in a case of Precursor T Cell ALL
  Turkey Journal and Hematology : 25 : 201 to 204 : 208
  Association between Plasma Homocystine and Reboflavin Study in Acute Lymphoblastic Leukemia Children

Dr. B. S. Aruna Kumari
- Association between Plasma Homocystine and Reboflavin Study in Acute Lymphoblastic Leukemia Children


<table>
<thead>
<tr>
<th>OUT PATIENTS:</th>
<th>MALE</th>
<th>FEMALE</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. NEW CASES</td>
<td>371</td>
<td>220</td>
<td>591</td>
</tr>
<tr>
<td>2. FOLLOW-UP CASES</td>
<td>6951</td>
<td>4053</td>
<td>11004</td>
</tr>
</tbody>
</table>

IN-PATIENTS:  

1. ADMISSIONS 131 72 203
2. RE-ADMISSIONS 335 200 535
3. DISCHARGES 412 216 628
4. DEATH 23 6 29

KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY
Dr.M.H.MARIGOWDA ROAD, BANGALORE – 560 029

Department of Pediatric Oncology,
Annual Report for the Year 2010-2011

1. INTRODUCTION ABOUT THE DEPARTMENT INCLUDING ACTIVITIES:

Pediatric Oncology is functioning as a separate unit in the Department of Medical Oncology from July 1992. At the 41st Meeting of Governing Council held on 29th December 2008 it was created as Department of Pediatric oncology.

The Department of Pediatric Oncology was created as an independent Department with effect from 28th March 2009 as per Official Memorandum No..KMIO/EST/1/94/2008-09 dated 28.3.2009.

ACTIVITIES:

The Department trains D.M. students in Medical Oncology and Post-graduate students posted from various medical colleges of Karnataka.
The Department has also started a Fellowship Training Programme from January 2010 which trains the Fellows for a period of 2 years.

2. CONFERENCES/SEMINAR/WORKSHOPS CONDUCTED BY THE DEPARTMENT:

Nil

3. MAJOR EQUIPMENTS ADDED DURING THE YEAR 2010-2011

Nil

4. STAFF POSITION:

Dr. L. Appaji MBBS, MD, DM : Prof; & HOD

Dr. B. S. Aruna Kumari MBBS, MD, DM : Associate Professor

Dr. M. Padma MBBS, MD : "-

Dr. H. S. Mamatha MBBS : Assistant Surgeon

FELLOWSHIP TRAINEE

Dr. Kavitha S. Srivathsa

5. RESEARCH ACTIVITIES/PROJECTS COMPLETED PROJECTS ONGOING AND NEW PROJECTS UNDERTAKEN DURING THIS PERIOD (01.04.2010 to 31.03.2011)

Nil

6. PARTICIPATION AT CONFERENCE / SEMINAR/WORKSHOPs DURING THE YEAR 2010-2011 (01.04.2010 to 31.03.2011)

Dr. L. Appaji

- Annual CME Programme of Indian Academy of Pediatrics – Bangalore – July 2010
- South PEDICON 2010, Indian Academy of Paediatrics, Hassan, October 2010
- 10th Annual International Conference – Malignancies in Children – RFCON 2011-Feb 2011 at Delhi

Dr.B.S.Aruna Kumari

- Annual CME Programme of Indian Academy of Pediatrics – Bangalore – July 2010

Dr.M.Padma

Participated as a Faculty in CME In Lung Cancer – Update on Small Cell Lung Cancer at KMIO on 16.7.2010

7. PAPERS PUBLISHED IN NATIONAL AND INTERNATIONAL JOURNALS, ALONG WITH THE TITLE OF THE PAPER, AUTHORS NAME, NAME OF JOURNAL (1.04.2010 to 31.03.2011)

Dr.L.Appaji

- Methylene Tetrohydrofolate Reductase Gene Polymorphism and Risk of Acute Lymphoblastic Leukemia in Children
  Indian Journal of Cancer – Jan-March 2010; Vol 47 Issue 1
    - Hepatoblastoma : Experience from a Single Center
    - Langerhan’s Cell Histocytosis : A Single Institutional Experience
      Indian Journal of Medical & Pediatric Oncology, April-June 2010 , Vol 31, Issue 2
    - Prevelance of High Risk Human Papilloma Virus Genotype in Retinoblastoma

Dr.B.S.Aruna Kumari

- Methylene Tetrohydrofolate Reduction Gene Polymorphism and Risk of Acute Lymphoblastic Leukemia in Children
  Indian Journal of Cancer : Jan-March 2010 :Vol 47 Issue 1
    - Hepatoblastoma : Experience from a Single Center
    - Langerhan’s Cell Histocytosis : A Single Institutional Experience
      Indian Journal of Medical & Pediatric Oncology, April-June 2010 , Vol 31, Issue 2

<table>
<thead>
<tr>
<th>OUT PATIENTS:</th>
<th>MALE</th>
<th>FEMALE</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. NEW CASES</td>
<td>325</td>
<td>196</td>
<td>521</td>
</tr>
<tr>
<td>2. FOLLOW-UP CASES</td>
<td>7972</td>
<td>4448</td>
<td>12420</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IN-PATIENTS:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. ADMISSIONS</td>
</tr>
<tr>
<td>2. RE-ADMISSIONS</td>
</tr>
<tr>
<td>3. DISCHARGES</td>
</tr>
<tr>
<td>4. DEATH</td>
</tr>
</tbody>
</table>